Maybe it’s not so odd in regards to the patients who’s kidneys aren’t as damaged (so less albuminuria to reduce). Remembering that DMX-200 works on CCR2 receptors that inhibit inflammation, if that has occurred as a legacy effect in the kidneys of these patients with less damage & has a longer lasting effect, which Prof Packham mentioned if the legacy effect had occurred then it’s possible that 12 weeks on DMX-200 possibly could have changed the course of the disease.
This is what I meant by clinical significance RL, & a good thing we have that crossover design. So this could actually be a positive for treating patients who aren’t as sick with DMX-200. We don’t know yet, but Professor Packham did say they treat at 30mg/mmol (macro albuminuria) and not to do so, would be negligent.
Many questions, fingers crossed
- Forums
- ASX - By Stock
- Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
Maybe it’s not so odd in regards to the patients who’s kidneys...
-
- There are more pages in this discussion • 268 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $164.5M |
Open | High | Low | Value | Volume |
31.0¢ | 31.0¢ | 30.0¢ | $818.6K | 2.683M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 1874183 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 10850 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1874183 | 0.300 |
8 | 282104 | 0.295 |
16 | 1221907 | 0.290 |
8 | 239548 | 0.285 |
8 | 222379 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 10850 | 1 |
0.310 | 277820 | 4 |
0.315 | 291993 | 6 |
0.320 | 529798 | 8 |
0.325 | 144810 | 6 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
30.0¢ |
  |
Change
-0.005 ( 1.64 %) |
|||
Open | High | Low | Volume | ||
31.0¢ | 31.0¢ | 30.0¢ | 640607 | ||
Last updated 15.54pm 28/03/2024 ? |
Featured News
DXB (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online